Rakovina Stock Based Compensation vs Change To Account Receivables Analysis

RKV Stock

CAD 0.09 0.01 12.50%

Rakovina Therapeutics financial indicator trend analysis is much more than just breaking down Rakovina Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Rakovina Therapeutics is a good investment. Please check the relationship between Rakovina Therapeutics Stock Based Compensation and its Change To Account Receivables accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rakovina Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Stock Based Compensation vs Change To Account Receivables

Stock Based Compensation vs Change To Account Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Rakovina Therapeutics Stock Based Compensation account and Change To Account Receivables. At this time, the significance of the direction appears to have pay attention.

The correlation between Rakovina Therapeutics' Stock Based Compensation and Change To Account Receivables is -0.78. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Change To Account Receivables in the same time period over historical financial statements of Rakovina Therapeutics, assuming nothing else is changed. The correlation between historical values of Rakovina Therapeutics' Stock Based Compensation and Change To Account Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Rakovina Therapeutics are associated (or correlated) with its Change To Account Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change To Account Receivables has no effect on the direction of Stock Based Compensation i.e., Rakovina Therapeutics' Stock Based Compensation and Change To Account Receivables go up and down completely randomly.

Correlation Coefficient

-0.78

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Change To Account Receivables

Most indicators from Rakovina Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Rakovina Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rakovina Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is likely to drop to about 706.8 K in 2024. Issuance Of Capital Stock is expected to grow at the current pace this year

	2010	2022	2023	2024 (projected)
Reconciled Depreciation	412.7K	536.1K	616.5K	544.5K
Total Operating Expenses	2.5M	2.8M	2.5M	2.9M

Reconciled Depreciation Total Operating Expenses

Rakovina Therapeutics fundamental ratios Correlations

	Other Liab	Net Tangible Assets	Retained Earnings	Common Stock	Other Current Liab	Total Current Liabilities	Net Receivables	Total Current Assets	Total Assets	Total Stockholder Equity	Accounts Payable	Cash	Non Current Assets Total	Common Stock Shares Outstanding	Total Liab	Net Invested Capital	Capital Stock	Net Working Capital	Intangible Assets	Net Debt	Long Term Debt
Other Liab		-0.71	0.65	-0.69	-0.71	-0.73	-0.57	-0.57	0.58	0.58	-0.34	0.58	0.51	-0.24	-0.45	0.58	-0.23	0.58	0.51	0.39	0.39
Net Tangible Assets	-0.71		-0.97	1.0	1.0	0.98	0.76	0.75	-0.86	-0.84	0.49	-0.86	-0.82	0.53	0.72	-0.86	0.52	-0.86	-0.82	-0.68	-0.68
Retained Earnings	0.65	-0.97		-0.97	-0.97	-0.96	-0.6	-0.57	0.95	0.94	-0.6	0.95	0.9	-0.56	-0.82	0.95	-0.55	0.95	0.9	0.76	0.76
Common Stock	-0.69	1.0	-0.97		1.0	0.98	0.76	0.74	-0.86	-0.84	0.49	-0.86	-0.82	0.53	0.72	-0.86	0.52	-0.86	-0.82	-0.69	-0.69
Other Current Liab	-0.71	1.0	-0.97	1.0		0.98	0.76	0.75	-0.86	-0.84	0.49	-0.86	-0.82	0.53	0.72	-0.86	0.52	-0.86	-0.82	-0.68	-0.68
Total Current Liabilities	-0.73	0.98	-0.96	0.98	0.98		0.75	0.73	-0.84	-0.84	0.57	-0.83	-0.76	0.38	0.7	-0.84	0.36	-0.83	-0.76	-0.61	-0.61
Net Receivables	-0.57	0.76	-0.6	0.76	0.76	0.75		0.98	-0.33	-0.32	0.21	-0.33	-0.35	0.29	0.32	-0.33	0.29	-0.33	-0.35	-0.33	-0.33
Total Current Assets	-0.57	0.75	-0.57	0.74	0.75	0.73	0.98		-0.3	-0.27	0.08	-0.3	-0.27	0.19	0.2	-0.3	0.19	-0.3	-0.27	-0.21	-0.21
Total Assets	0.58	-0.86	0.95	-0.86	-0.86	-0.84	-0.33	-0.3		0.99	-0.63	1.0	0.95	-0.6	-0.86	1.0	-0.59	1.0	0.95	0.81	0.81
Total Stockholder Equity	0.58	-0.84	0.94	-0.84	-0.84	-0.84	-0.32	-0.27	0.99		-0.73	0.98	0.94	-0.54	-0.9	0.99	-0.52	0.98	0.94	0.8	0.8
Accounts Payable	-0.34	0.49	-0.6	0.49	0.49	0.57	0.21	0.08	-0.63	-0.73		-0.59	-0.66	0.31	0.85	-0.63	0.29	-0.59	-0.66	-0.67	-0.67
Cash	0.58	-0.86	0.95	-0.86	-0.86	-0.83	-0.33	-0.3	1.0	0.98	-0.59		0.95	-0.61	-0.85	1.0	-0.59	1.0	0.95	0.8	0.8
Non Current Assets Total	0.51	-0.82	0.9	-0.82	-0.82	-0.76	-0.35	-0.27	0.95	0.94	-0.66	0.95		-0.8	-0.94	0.95	-0.79	0.95	1.0	0.95	0.95
Common Stock Shares Outstanding	-0.24	0.53	-0.56	0.53	0.53	0.38	0.29	0.19	-0.6	-0.54	0.31	-0.61	-0.8		0.73	-0.6	1.0	-0.61	-0.8	-0.91	-0.91
Total Liab	-0.45	0.72	-0.82	0.72	0.72	0.7	0.32	0.2	-0.86	-0.9	0.85	-0.85	-0.94	0.73		-0.87	0.71	-0.85	-0.94	-0.95	-0.95
Net Invested Capital	0.58	-0.86	0.95	-0.86	-0.86	-0.84	-0.33	-0.3	1.0	0.99	-0.63	1.0	0.95	-0.6	-0.87		-0.58	1.0	0.95	0.81	0.81
Capital Stock	-0.23	0.52	-0.55	0.52	0.52	0.36	0.29	0.19	-0.59	-0.52	0.29	-0.59	-0.79	1.0	0.71	-0.58		-0.59	-0.79	-0.9	-0.9
Net Working Capital	0.58	-0.86	0.95	-0.86	-0.86	-0.83	-0.33	-0.3	1.0	0.98	-0.59	1.0	0.95	-0.61	-0.85	1.0	-0.59		0.95	0.8	0.8
Intangible Assets	0.51	-0.82	0.9	-0.82	-0.82	-0.76	-0.35	-0.27	0.95	0.94	-0.66	0.95	1.0	-0.8	-0.94	0.95	-0.79	0.95		0.95	0.95
Net Debt	0.39	-0.68	0.76	-0.69	-0.68	-0.61	-0.33	-0.21	0.81	0.8	-0.67	0.8	0.95	-0.91	-0.95	0.81	-0.9	0.8	0.95		1.0
Long Term Debt	0.39	-0.68	0.76	-0.69	-0.68	-0.61	-0.33	-0.21	0.81	0.8	-0.67	0.8	0.95	-0.91	-0.95	0.81	-0.9	0.8	0.95	1.0

Click cells to compare fundamentals

Rakovina Therapeutics Account Relationship Matchups

Rakovina Therapeutics fundamental ratios Accounts

		2019	2020	2021	2022	2023	2024 (projected)
Retained Earnings		(1.1M)	(13.0)	(5.5M)	(8.3M)	(10.9M)	(10.4M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Rakovina Stock Analysis

When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC